ABOUT US
Company Profile
Immorna, founded in 2019, is a globally leading clinical-stage biotechnology company dedicated to the development of coding RNA vaccines and therapeutics.
Leveraging our advanced messenger RNA (mRNA) and self-replicating RNA (srRNA) technology platforms, proprietary delivery system platforms, and AI-enabled drug discovery platforms, we have rapidly built a diverse and high-potential product pipeline. Our R&D achievements span multiple critical fields including infectious diseases, cancer, and autoimmune diseases, with several candidate products already advancing into clinical development stages in both the United States and China.
Immorna is committed to technological innovation. Through unique antigen structure design and our next-generation innate-silent srRNA (isRNA) technology, we can precisely regulate the protein expression levels, duration of expression, and innate immune activation of coding RNA vaccines and therapeutics, aiming to achieve superior immunogenicity and safety profiles. More importantly, our proprietary ready-to-use (RTU) thermostable delivery system significantly enhances the storage stability of RNA vaccines, holding the potential to overcome the limitations of ultra-cold chain logistics. This lays a solid foundation for future product accessibility and commercialization.
Building on the vast prospects and validated success of coding RNA technology, we are vigorously advancing key projects including JCXH-105 (shingles vaccine), JCXH-108 (RSV vaccine), JCXH-211 (solid tumor therapy), and JCXH-213 (in vivo CAR therapy). We aim to fully realize the potential of coding RNA technology, striving to become a pioneer in leading industry development, bringing breakthrough medical advancements to patients worldwide, and improving human health.
Corporate Mission
To utilize next-generation mRNA platforms and innovative delivery technology to develop life-saving medicines for patients.
Development History
Global Distribution
Research Triangle Park, NC
Hangzhou
Shanghai
The RTP site launched in early 2022. It is quickly becoming Immorna’s powerhouse of innovation and will drive development of new RNA modalities and delivery vehicles. This R&D center spearheads application of RNA platform technologies in new disease areas. The US site is also hub of Immorna’s global clinical development team.
In the heart of Zhejiang Province on the east coast of China, Hangzhou is the home of Immorna’s 70,000 sf CMC labs and offices. The city also houses Immorna’s 30,000 sf GMP pilot plant, which has the capability to manufacture investigational drugs and vaccines for large scale clinical trials. In addition, Immorna’s future commercial manufacturing plant is currently in development in Hangzhou.
Sitting in the fast-growing biotech hotspot in Shanghai are Immorna’s state-of-the-art preclinical research labs, over 20,000 sf in size. This site drives the preclinical Proof-of-Concept studies for many programs in Immorna’s pipeline.
Company Team
Zihao Wang, PhD
Zhijun Guo, MBA
Yuanqing Liu, MD, PhD
NgocDiep Le, MD, PhD
Jeffrey Ulmer, PhD
Zhang Kexin, MS
Marcin Bugno, PhD
Board of Directors
Zihao Wang, PhD
Zhijun Guo, MBA
Yuanqing Liu, MD, PhD
NgocDiep Le, MD, PhD
Jeffrey Ulmer, PhD
Zhang Kexin, MS
Marcin Bugno, PhD
MENU
TEL
Research Triangle Park, NC, USA
+1 (984) 888-0460
Hangzhou/Shanghai, China
0571-821 76090
Statement
Privacy Statement
This privacy policy discloses the privacy practices for Immorna (Hangzhou) Biotechnology Co., Ltd. All Tools. This privacy policy applies solely to information collected by this web site. It will notify you of the following:
What personally identifiable information is collected from you through the web site, how it is used and with whom it may be shared.
What choices are available to you regarding the use of your data.
The security procedures in place to protect the misuse of your information.
How you can correct any inaccuracies in the information.
Information Collection, Use, and Sharing
We are the sole owners of the information collected on this site. We only have access to/collect information that you voluntarily give us via email or other direct contact from you. We will not sell or rent this information to anyone.
We will use your information to respond to you, regarding the reason you contacted us. We will not share your information with any third party outside of our organization, other than as necessary to fulfill your request, e.g. to ship an order.
Unless you ask us not to, we may contact you via email in the future to tell you about specials, new products or services, or changes to this privacy policy.
Your Access to and Control Over Information
You may opt out of any future contacts from us at any time. You can do the following at any time by contacting us via the email address or phone number given on our website:
See what data we have about you, if any.
Change/correct any data we have about you.
Have us delete any data we have about you.
Express any concern you have about our use of your data.
Security
We take precautions to protect your information. When you submit sensitive information via the website, your information is protected both online and offline.
Wherever we collect sensitive information (such as credit card data), that information is encrypted and transmitted to us in a secure way. You can verify this by looking for a closed lock icon at the bottom of your web browser, or looking for “https” at the beginning of the address of the web page.
While we use encryption to protect sensitive information transmitted online, we also protect your information offline. Only employees who need the information to perform a specific job (for example, billing or customer service) are granted access to personally identifiable information. The computers/servers in which we store personally identifiable information are kept in a secure environment.
Updates
Our Privacy Policy may change from time to time and all updates will be posted on this page.
If you feel that we are not abiding by this privacy policy, you should contact us immediately via e-mail info@immorna.com